Cocrystal Pharma Stock Performance
| COCP Stock | USD 2.07 0.03 1.43% |
On a scale of 0 to 100, Cocrystal Pharma holds a performance score of 6. The firm shows a Beta (market volatility) of 0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cocrystal Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cocrystal Pharma is expected to be smaller as well. Please check Cocrystal Pharma's standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Cocrystal Pharma's price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Cocrystal Pharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental indicators, Cocrystal Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.64) | Five Day Return (3.03) | Year To Date Return 17.36 | Ten Year Return (98.85) | All Time Return (94.32) |
Last Split Factor 1:12 | Dividend Date 2018-01-24 | Last Split Date 2022-10-11 |
1 | Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts | 09/26/2024 |
2 | Acquisition by Martin James Joseph of 300000 shares of Cocrystal Pharma subject to Rule 16b-3 | 09/27/2024 |
3 | Acquisition by Japour Anthony J of 14924 shares of Cocrystal Pharma subject to Rule 16b-3 | 10/09/2024 |
4 | Acquisition by Block David S of 108696 shares of Cocrystal Pharma at 0.92 subject to Rule 16b-3 | 10/10/2024 |
5 | Cocrystal Pharmas Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins | 10/31/2024 |
6 | Cocrystal Pharma GAAP EPS of -0.49 beats by 0.08 | 11/13/2024 |
7 | Acquisition by Linscott Walt Addison of 1200000 shares of Cocrystal Pharma at 0.98 subject to Rule 16b-3 | 11/29/2024 |
| Begin Period Cash Flow | 37.2 M |
Cocrystal |
Cocrystal Pharma Relative Risk vs. Return Landscape
If you would invest 172.00 in Cocrystal Pharma on September 3, 2024 and sell it today you would earn a total of 35.00 from holding Cocrystal Pharma or generate 20.35% return on investment over 90 days. Cocrystal Pharma is currently generating 0.4034% in daily expected returns and assumes 4.9972% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Cocrystal, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cocrystal Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cocrystal Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cocrystal Pharma, and traders can use it to determine the average amount a Cocrystal Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | COCP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.0 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.4 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cocrystal Pharma is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cocrystal Pharma by adding it to a well-diversified portfolio.
Cocrystal Pharma Fundamentals Growth
Cocrystal Stock prices reflect investors' perceptions of the future prospects and financial health of Cocrystal Pharma, and Cocrystal Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cocrystal Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 9.87 M | ||||
| Shares Outstanding | 10.17 M | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (8.79 M) | ||||
| EBITDA | (19.37 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Earnings Per Share | (1.84) X | ||||
| Market Capitalization | 21.36 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
About Cocrystal Pharma Performance
Assessing Cocrystal Pharma's fundamental ratios provides investors with valuable insights into Cocrystal Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cocrystal Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 101.98 | 96.88 | |
| Return On Tangible Assets | (0.58) | (0.60) | |
| Return On Capital Employed | (0.66) | (0.70) | |
| Return On Assets | (0.58) | (0.60) | |
| Return On Equity | (0.68) | (0.65) |
Things to note about Cocrystal Pharma performance evaluation
Checking the ongoing alerts about Cocrystal Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cocrystal Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cocrystal Pharma had very high historical volatility over the last 90 days | |
| Cocrystal Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (17.98 M) with loss before overhead, payroll, taxes, and interest of (8.79 M). | |
| Cocrystal Pharma currently holds about 51.03 M in cash with (14.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cocrystal Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 32.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Linscott Walt Addison of 1200000 shares of Cocrystal Pharma at 0.98 subject to Rule 16b-3 |
- Analyzing Cocrystal Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cocrystal Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Cocrystal Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cocrystal Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cocrystal Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cocrystal Pharma's stock. These opinions can provide insight into Cocrystal Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cocrystal Stock Analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.